- Home
- RGC vs STTK Comparison
RGC vs STTK Comparison
Compare RGC & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- STTK
- Stock Information
- Founded
- RGC 2014
- STTK 2016
- Country
- RGC Hong Kong
- STTK United States
- Employees
- RGC N/A
- STTK N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- RGC Health Care
- STTK Health Care
- Exchange
- RGC Nasdaq
- STTK Nasdaq
- Market Cap
- RGC 105.3M
- STTK 56.8M
- IPO Year
- RGC 2021
- STTK 2020
- Fundamental
- Price
- RGC $4.86
- STTK $1.12
- Analyst Decision
- RGC
- STTK Hold
- Analyst Count
- RGC 0
- STTK 3
- Target Price
- RGC N/A
- STTK $2.00
- AVG Volume (30 Days)
- RGC 8.8K
- STTK 182.2K
- Earning Date
- RGC 10-25-2024
- STTK 02-27-2025
- Dividend Yield
- RGC N/A
- STTK N/A
- EPS Growth
- RGC N/A
- STTK N/A
- EPS
- RGC N/A
- STTK N/A
- Revenue
- RGC N/A
- STTK $6,435,000.00
- Revenue This Year
- RGC N/A
- STTK $313.04
- Revenue Next Year
- RGC N/A
- STTK N/A
- P/E Ratio
- RGC N/A
- STTK N/A
- Revenue Growth
- RGC N/A
- STTK 382.75
- 52 Week Low
- RGC $3.03
- STTK $0.94
- 52 Week High
- RGC $32.44
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- RGC 44.96
- STTK 43.75
- Support Level
- RGC $4.75
- STTK $1.13
- Resistance Level
- RGC $5.21
- STTK $1.39
- Average True Range (ATR)
- RGC 0.30
- STTK 0.11
- MACD
- RGC 0.04
- STTK 0.00
- Stochastic Oscillator
- RGC 23.87
- STTK 18.18
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.